|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4800 Deerwood Campus Parkway |
Address2 |
|
| City | Jacksonville |
State | FL |
Zip Code | 32246 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103191-12
|
||||||||
|
6. House ID# 424860000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Mai-Kim Norman |
Date | 4/21/2025 1:07:20 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues:
Same-day billing restrictions in Medicaid; Medicare Advantage & MA Rate Notice; Medicare/Transparency; Medicaid Cuts; Mental Health Care, Youth Mental Health; Site neutral payment reform; Healthy Equity Index reward factor; Value Base Care
Bills:
H.R. 7149, Equal Access to Specialty Care Everywhere (EASE) Act of 2024
To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model to improve access to specialty health services for certain Medicare and Medicaid beneficiaries.
Sponsor: Rep. Steel, Michelle [R-CA-45]
S.4078 - EASE Act of 2024
To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model to improve access to specialty health services for certain Medicare and Medicaid beneficiaries.
Sponsor: Sen. Mullin, Markwayne [R-OK]
H.R.5746 - Addressing Whole Health in Medicare Advantage Act
To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
Sponsor: Rep. Bilirakis, Gus M. [R-FL-12]
H.R. 7623, Telehealth Modernization Act
To amend title XVIII of the Social Security Act to make permanent certain telehealth flexibilities under the Medicare program.
Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]
H.R. 7996, Improving CARE for Youth Act
To amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services and primary care services furnished on the same day.
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
S.2556 - Improving CARE for Youth Act
To amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services and primary care services furnished on the same day.
Sponsor: Sen. Carper, Thomas R. [D-DE]
H.R.1227 - Alternatives to PAIN Act
To amend title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs under part D of the Medicare program.
Sponsor: Rep. Miller-Meeks, Mariannette [R-IA-1]
H.R.2433 - Reducing Medically Unnecessary Delays in Care Act of 2025
To ensure that prior authorization medical decisions under Medicare are determined by physicians.
Sponsor: Rep. Green, Mark E. [R-TN-7]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues:
340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy
Bills:
S. 1114, Expanding Access to Low-Cost Generics Act
To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
Sponsor: Sen. Smith, Tina [D-MN]
S. 2305 - Biosimilar Red Tape Elimination Act
To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Sponsor: Sen. Lee, Mike [R-UT]
S. 148 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen. Amy Klobuchar (D-MN)
S.1339 - Pharmacy Benefit Manager Reform Act
To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
Sponsor: Sen. Sanders, Bernard [I-VT]
S. 775, Increasing Transparency in Generic Drug Applications
To provide for increased transparency in generic drug applications.
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
S. 150 - Affordable Prescriptions for Patients Act of 2023
To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. Cornyn, John [R-TX]
H.R.9070 - Affordable Prescriptions for Patients Act of 2024
To amend title 35, United States Code, to prohibit product hopping, and for other purposes.
Sponsor: Rep. Issa, Darrell [R-CA-48]
S.1542, DRUG Act
To improve services provided by pharmacy benefit managers.
Sponsor: Sen. Marshall, Roger [R-KS]
S. 142 - Preserve Access to Affordable Generics and Biosimilars Act
To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen. Klobuchar, Amy [D-MN]
S. 1067, Ensuring Timely Access to Generics Act
To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S.1041 - Affordable Prescriptions for Patients Act
A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.
Sponsor: Sen. Cornyn, John [R-TX]
S.1040 - Drug Competition Enhancement Act
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. Cornyn, John [R-TX]
S.1096 - Preserve Access to Affordable Generics and Biosimilars Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen. Klobuchar, Amy [D-MN]
S.1095 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen. Klobuchar, Amy [D-MN]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
tom |
giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |